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specific AOPP prepared in vitro by exposure of human
serum albumin (HSA) to HOCl displayed properties sim-
ilar, yet not identical, to those products isolated from
blood of uremic patients. According to the authors, dif-
ferent properties may originate from a heterogeneous
nature of the whole AOPP. This indeed may be a
very important albeit not sufficiently recognized fact. In
1995, we reported on a macromolecular protein com-
plex (MPC) present in increased quantities in blood
of diabetic patients with nephropathy [2], the molec-
ular properties of which are similar, if not identi-
cal, to AOPP. Although we have suspected that MPC
may contain free radical–modified HSA, no such anti-
gen could be detected by a specific enzyme-linked im-
munosorbent assay (ELISA) test. However, we have
subsequently documented the presence in MPC of
both fibrinogen A alpha chain and triglyceride-rich
lipoprotein.
Moreover, we were able to prepare a similar complex
in vitro by exposure of plasma to a hydroxyl radical gen-
erating system [3]. Because the system contained ascorbic
acid and a transition metal, it was suggestive that MPC
may be formed in vitro by a reductive rather than oxida-
tive conditions.
In conclusion, it appears that both MPC and AOPP
represent the same class of free radical–modified proteins
circulating in blood of uremic patients. It is, however, not
clear whether these products are formed by the action of
oxidizing or reducing radical oxygen species [4].
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Reply from the Authors
We wish to thank Dr. Lipinski for his most perti-
nent remarks. We agree that the species isolated from
the blood of diabetic patients, macromolecular complex
protein complex (MPC), described in the laboratory of
Dr. Lipinski could, most likely, be included in the group
of oxidatively-modified proteins including advanced oxi-
dation protein products (AOPP) [1].
We have recently obtained information on the bio-
chemical and molecular characteristics of AOPP. The use
of various analytical techniques enabled localizing and
identifying the main oxidized proteins in hemodialysis
(HD) plasma with human serurm albumin (HAS). To in-
terpret the spectral modifications detected in HD plasma
fractions we described in detail some structural modifi-
cations that occur as a result of plasma or HSA treat-
ment with HOCl. Our results indicate that HOCl, and
not NO2 generated by myeloperoxidase (MPO), repre-
sents a pathway for AOPP production in plasma proteins
exposed to activated phagocytes (manuscript submitted
for publication). However, this pathway is not exclusive
and other oxido-reduction reactions may occur.
The fact that MPC did not react in an enzyme-linked
immunosorbent assay (ELISA) specific for the detection
of oxidized proteins might be due to restricted epitopes,
which might not be apparent on MPC. Therefore, the
presence of oxidatively modified protein features in MPC
could not be ruled out. Interestingly, MPC contained
fibrinogen A alpha chain and triglyceride-rich lipopro-
tein, the latter also being present in plasma AOPP. In
our opinion, the evidence that MPC could be obtained
by exposing plasma to hydroxyl radical confirmed that
MPC could be generated by oxidants, even if this hy-
droxyl radical–generating system involved reducing sys-
tems such as ascorbic acid and transition metals. Indeed,
protein reduction would prevent disulfide bridges and
decreased protein cross-linking.
The report of the group of Dr. Lipinski extends the
concept of the biologic and pathophysiologic relevance of
oxidatively modified proteins. We have recently reported
that AOPP could induce interleukin (IL)-8 synthesis
by neutrophils and by monocytes, thus corroborating
our previous results that demonstrate that AOPP are in-
flammatory mediators [2]. Therefore, further investiga-
tion on the involvement of AOPP and/or MPC should be
performed, especially in diabetic or in uremic patients.
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